References analysis of the Wikipedia article "Chłoniak Hodgkina" in the Polish version

doi.org

Zahra Mozaheb. Epidemiology of hodgkin’s lymphoma. „Health”, 2013. DOI: 10.4236/health.2013.55A003.

W. Townsend, D. Linch. Hodgkin’s lymphoma in adults. „Lancet”. 380 (9844), s. 836–847, wrzesień 2012. DOI: 10.1016/S0140-6736(12)60035-X. PMID: 22835602.

S.J. Hyun, S.C. Rhim, J. Huh. Simultaneous Occurrence of Hodgkin’s Lymphoma and Langerhans Cell Histiocytosis of the Spine: A Rare Combination. „J Korean Neurosurg Soc”. 47 (4), s. 302–305, kwiecień 2010. DOI: 10.3340/jkns.2010.47.4.302. PMID: 20461174.

P. Shenoy, A. Maggioncalda, N. Malik, C.R. Flowers. Incidence patterns and outcomes for hodgkin lymphoma patients in the United States. „Adv Hematol”. 2011, s. 725219, 2011. DOI: 10.1155/2011/725219. PMID: 21197477.

C. Agostinelli, S. Pileri. Pathobiology of hodgkin lymphoma. „Mediterr J Hematol Infect Dis”. 6 (1), s. e2014040, 2014. DOI: 10.4084/MJHID.2014.040. PMID: 24959337.

L.B. Smith. Nodular lymphocyte predominant Hodgkin lymphoma: diagnostic pearls and pitfalls. „Arch Pathol Lab Med”. 134 (10), s. 1434–1439, październik 2010. DOI: 10.1043/2010-0207-OA.1. PMID: 20923296.

R. Küppers, A. Engert, M.L. Hansmann. Hodgkin lymphoma. „J Clin Invest”. 122 (10), s. 3439–3447, październik 2012. DOI: 10.1172/JCI61245. PMID: 23023715.

K. Farrell, R.F. Jarrett. The molecular pathogenesis of Hodgkin lymphoma. „Histopathology”. 58 (1), s. 15–25, styczeń 2011. DOI: 10.1111/j.1365-2559.2010.03705.x. PMID: 21261680.

M. Janz, S. Mathas. The pathogenesis of classical Hodgkin’s lymphoma: what can we learn from analyses of genomic alterations in Hodgkin and Reed-Sternberg cells?. „Haematologica”. 93 (9), s. 1292–1295, wrzesień 2008. DOI: 10.3324/haematol.13614. PMID: 18757849.

I. Schwering, A. Bräuninger, U. Klein, B. Jungnickel i inni. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. „Blood”. 101 (4), s. 1505–1512, luty 2003. DOI: 10.1182/blood-2002-03-0839. PMID: 12393731.

R. Küppers. Molecular biology of Hodgkin lymphoma. „Hematology Am Soc Hematol Educ Program”, s. 491–496, 2009. DOI: 10.1182/asheducation-2009.1.491. PMID: 20008234.

M. Vockerodt, F.Z. Cader, C. Shannon-Lowe, P. Murray. Epstein-Barr virus and the origin of Hodgkin lymphoma. „Chin J Cancer”. 33 (12), s. 591–597, grudzień 2014. DOI: 10.5732/cjc.014.10193. PMID: 25418190.

L.L. Laichalk, D.A. Thorley-Lawson. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. „J Virol”. 79 (2), s. 1296–1307, styczeń 2005. DOI: 10.1128/JVI.79.2.1296-1307.2005. PMID: 15613356.

E. Schaadt, B. Baier, J. Mautner, G.W. Bornkamm i inni. Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation. „J Gen Virol”. 86 (Pt 3), s. 551–559, marzec 2005. DOI: 10.1099/vir.0.80440-0. PMID: 15722514.

K. Vrzalikova, M. Vockerodt, S. Leonard, A. Bell i inni. Down-regulation of BLIMP1α by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. „Blood”. 117 (22), s. 5907–5917, czerwiec 2011. DOI: 10.1182/blood-2010-09-307710. PMID: 21411757.

M. Vockerodt, W. Wei, E. Nagy, Z. Prouzova i inni. Suppression of the LMP2A target gene, EGR-1, protects Hodgkin’s lymphoma cells from entry to the EBV lytic cycle. „J Pathol”. 230 (4), s. 399–409, sierpień 2013. DOI: 10.1002/path.4198. PMID: 23592216.

F. Emmerich, S. Theurich, M. Hummel, A. Haeffker i inni. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. „J Pathol”. 201 (3), s. 413–420, listopad 2003. DOI: 10.1002/path.1454. PMID: 14595753.

R. Schmitz, M.L. Hansmann, V. Bohle, J.I. Martin-Subero i inni. TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. „J Exp Med”. 206 (5), s. 981–989, maj 2009. DOI: 10.1084/jem.20090528. PMID: 19380639.

T. Diaz, A. Navarro, G. Ferrer, B. Gel i inni. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. „PLoS One”. 6 (4), s. e18856, 2011. DOI: 10.1371/journal.pone.0018856. PMID: 21533094.

W. Vainchenker, S.N. Constantinescu. JAK/STAT signaling in hematological malignancies. „Oncogene”. 32 (21), s. 2601–2613, maj 2013. DOI: 10.1038/onc.2012.347. PMID: 22869151.

M.A. Weniger, I. Melzner, C.K. Menz, S. Wegener i inni. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. „Oncogene”. 25 (18), s. 2679–2684, kwiecień 2006. DOI: 10.1038/sj.onc.1209151. PMID: 16532038.

C. Steidl, J.M. Connors, R.D. Gascoyne. Molecular pathogenesis of Hodgkin’s lymphoma: increasing evidence of the importance of the microenvironment. „J Clin Oncol”. 29 (14), s. 1812–1826, maj 2011. DOI: 10.1200/JCO.2010.32.8401. PMID: 21483001.

S.M. Ansell. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. „Am J Hematol”. 89 (7), s. 771–779, lipiec 2014. DOI: 10.1002/ajh.23750. PMID: 24953862.

A. Engert, J. Franklin, H.T. Eich, C. Brillant i inni. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin’s lymphoma: final results of the GHSG HD7 trial. „J Clin Oncol”. 25 (23), s. 3495–3502, sierpień 2007. DOI: 10.1200/JCO.2006.07.0482. PMID: 17606976.

P. Seam, J.E. Janik, D.L. Longo, V.T. Devita. Role of chemotherapy in Hodgkin’s lymphoma. „Cancer J”. 15 (2). s. 150–154. DOI: 10.1097/PPO.0b013e3181a27018. PMID: 19390311.

S. Laskar, T. Gupta, S. Vimal, M.A. Muckaden i inni. Consolidation radiation after complete remission in Hodgkin’s disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. „J Clin Oncol”. 22 (1), s. 62–68, styczeń 2004. DOI: 10.1200/JCO.2004.01.021. PMID: 14657226.

D.J. Straus, C.S. Portlock, J. Qin, J. Myers i inni. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. „Blood”. 104 (12), s. 3483–3489, grudzień 2004. DOI: 10.1182/blood-2004-04-1311. PMID: 15315964.

A. Engert, A. Plütschow, H.T. Eich, A. Lohri i inni. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. „N Engl J Med”. 363 (7), s. 640–652, sierpień 2010. DOI: 10.1056/NEJMoa1000067. PMID: 20818855.

G. Bonadonna, V. Bonfante, S. Viviani, A. Di Russo i inni. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. „J Clin Oncol”. 22 (14), s. 2835–2841, lipiec 2004. DOI: 10.1200/JCO.2004.12.170. PMID: 15199092.

H.T. Eich, V. Diehl, H. Görgen, T. Pabst i inni. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. „J Clin Oncol”. 28 (27), s. 4199–4206, wrzesień 2010. DOI: 10.1200/JCO.2010.29.8018. PMID: 20713848.

A. Engert, P. Schiller, A. Josting, R. Herrmann i inni. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group. „J Clin Oncol”. 21 (19), s. 3601–3608, październik 2003. DOI: 10.1200/JCO.2003.03.023. PMID: 12913100.

S. Sasse, B. Klimm, H. Görgen, M. Fuchs i inni. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin’s lymphoma. „Ann Oncol”. 23 (11), s. 2953–2959, listopad 2012. DOI: 10.1093/annonc/mds110. PMID: 22767583.

B. von Tresckow, A. Plütschow, M. Fuchs, B. Klimm i inni. Dose-intensification in early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. „J Clin Oncol”. 30 (9), s. 907–913, marzec 2012. DOI: 10.1200/JCO.2011.38.5807. PMID: 22271480.

P.J. Hoskin, L. Lowry, A. Horwich, A. Jack i inni. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin’s Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. „J Clin Oncol”. 27 (32), s. 5390–5396, listopad 2009. DOI: 10.1200/JCO.2009.23.3239. PMID: 19738111.

L.I. Gordon, F. Hong, R.I. Fisher, N.L. Bartlett i inni. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). „J Clin Oncol”. 31 (6), s. 684–691, luty 2013. DOI: 10.1200/JCO.2012.43.4803. PMID: 23182987.

G.P. Canellos, J.R. Anderson, K.J. Propert, N. Nissen i inni. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. „N Engl J Med”. 327 (21), s. 1478–1484, listopad 1992. DOI: 10.1056/NEJM199211193272102. PMID: 1383821.

V. Diehl, J. Franklin, M. Pfreundschuh, B. Lathan i inni. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. „N Engl J Med”. 348 (24), s. 2386–2395, czerwiec 2003. DOI: 10.1056/NEJMoa022473. PMID: 12802024.

A. Engert, V. Diehl, J. Franklin, A. Lohri i inni. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. „J Clin Oncol”. 27 (27), s. 4548–4554, wrzesień 2009. DOI: 10.1200/JCO.2008.19.8820. PMID: 19704068.

P. Borchmann, H. Haverkamp, V. Diehl, T. Cerny i inni. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. „J Clin Oncol”. 29 (32), s. 4234–4242, listopad 2011. DOI: 10.1200/JCO.2010.33.9549. PMID: 21990399.

A. Engert, H. Haverkamp, C. Kobe, J. Markova i inni. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. „Lancet”. 379 (9828), s. 1791–1799, maj 2012. DOI: 10.1016/S0140-6736(11)61940-5. PMID: 22480758.

N. Skoetz, S. Trelle, M. Rancea, H. Haverkamp i inni. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin’s lymphoma: a systematic review and network meta-analysis. „Lancet Oncol”. 14 (10), s. 943–952, wrzesień 2013. DOI: 10.1016/S1470-2045(13)70341-3. PMID: 23948348.

F. Merli, S. Luminari, P.G. Gobbi, N. Cascavilla i inni. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. „J Clin Oncol”, grudzień 2015. DOI: 10.1200/JCO.2015.62.4817. PMID: 26712220.

B.M. Aleman, J.M. Raemaekers, R. Tomiŝiĉ, M.H. Baaijens i inni. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin’s lymphoma. „Int J Radiat Oncol Biol Phys”. 67 (1), s. 19–30, styczeń 2007. DOI: 10.1016/j.ijrobp.2006.08.041. PMID: 17097834.

P.W. Johnson, M.R. Sydes, B.W. Hancock, M. Cullen i inni. Consolidation radiotherapy in patients with advanced Hodgkin’s lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). „J Clin Oncol”. 28 (20), s. 3352–3359, lipiec 2010. DOI: 10.1200/JCO.2009.26.0323. PMID: 20498402.

N. Schmitz, B. Pfistner, M. Sextro, M. Sieber i inni. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. „Lancet”. 359 (9323), s. 2065–2071, czerwiec 2002. DOI: 10.1016/S0140-6736(02)08938-9. PMID: 12086759.

B. Sirohi, D. Cunningham, R. Powles, F. Murphy i inni. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. „Ann Oncol”. 19 (7), s. 1312–1319, lipiec 2008. DOI: 10.1093/annonc/mdn052. PMID: 18356139.

A.J. Moskowitz, P.A. Hamlin, M.A. Perales, J. Gerecitano i inni. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. „J Clin Oncol”. 31 (4), s. 456–460, luty 2013. DOI: 10.1200/JCO.2012.45.3308. PMID: 23248254.

T.A. Fehniger, S. Larson, K. Trinkaus, M.J. Siegel i inni. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. „Blood”. 118 (19), s. 5119–5125, listopad 2011. DOI: 10.1182/blood-2011-07-362475. PMID: 21937701.

P.B. Johnston, D.J. Inwards, J.P. Colgan, B.R. Laplant i inni. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. „Am J Hematol”. 85 (5), s. 320–324, maj 2010. DOI: 10.1002/ajh.21664. PMID: 20229590.

A. Josting, L. Nogová, J. Franklin, J.P. Glossmann i inni. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. „J Clin Oncol”. 23 (7), s. 1522–1529, marzec 2005. DOI: 10.1200/JCO.2005.05.022. PMID: 15632410.

K.M. Kelly. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. „Blood”. 126 (22), s. 2452–2458, listopad 2015. DOI: 10.1182/blood-2015-07-641035. PMID: 26582374.

A. Englund, C. Hopstadius, G. Enblad, G. Gustafsson i inni. Hodgkin lymphoma-a survey of children and adolescents treated in Sweden 1985-2009. „Acta Oncol”. 54 (1), s. 41–48, styczeń 2015. DOI: 10.3109/0284186X.2014.948058. PMID: 25203597.

J.M. Yeh, L. Diller. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks. „Blood”. 120 (11), s. 2195–2202, wrzesień 2012. DOI: 10.1182/blood-2012-02-409821. PMID: 22826564.

C. Mauz-Körholz, M.L. Metzger, K.M. Kelly, C.L. Schwartz i inni. Pediatric Hodgkin Lymphoma. „J Clin Oncol”. 33 (27), s. 2975–2985, wrzesień 2015. DOI: 10.1200/JCO.2014.59.4853. PMID: 26304892.

C.E. Allen, K.M. Kelly, C.M. Bollard. Pediatric lymphomas and histiocytic disorders of childhood. „Pediatr Clin North Am”. 62 (1), s. 139–165, luty 2015. DOI: 10.1016/j.pcl.2014.09.010. PMID: 25435117.

V. Ballova, J.U. Rüffer, H. Haverkamp, B. Pfistner i inni. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). „Ann Oncol”. 16 (1), s. 124–131, styczeń 2005. DOI: 10.1093/annonc/mdi023. PMID: 15598949.

A.M. Evens, F. Hong. How can outcomes be improved for older patients with Hodgkin lymphoma?. „J Clin Oncol”. 31 (12), s. 1502–1505, kwiecień 2013. DOI: 10.1200/JCO.2012.47.3058. PMID: 23509323.

M. Björkholm, E. Svedmyr, J. Sjöberg. How we treat elderly patients with Hodgkin lymphoma. „Curr Opin Oncol”. 23 (5), s. 421–428, wrzesień 2011. DOI: 10.1097/CCO.0b013e328348c6c1. PMID: 21681093.

B.D. Cheson, R.I. Fisher, S.F. Barrington, F. Cavalli i inni. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. „J Clin Oncol”. 32 (27), s. 3059–3068, wrzesień 2014. DOI: 10.1200/JCO.2013.54.8800. PMID: 25113753.

M. Koshy, A. Fairchild, C.H. Son, U. Mahmood. Improved survival time trends in Hodgkin’s lymphoma. „Cancer Med”. 5 (6), s. 997–1003, czerwiec 2016. DOI: 10.1002/cam4.655. PMID: 26999817.

I. Glimelius, S. Ekberg, M. Jerkeman, E.T. Chang i inni. Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics. „Am J Hematol”. 90 (12), s. 1128–1134, grudzień 2015. DOI: 10.1002/ajh.24184. PMID: 26349012.

R.L. Siegel, K.D. Miller, A. Jemal. Cancer statistics, 2015. „CA Cancer J Clin”. 65 (1). s. 5–29. DOI: 10.3322/caac.21254. PMID: 25559415.

G. Bonadonna, T. Hodgkin. Historical review of Hodgkin’s disease. „Br J Haematol”. 110 (3), s. 504–511, wrzesień 2000. DOI: 10.1046/j.1365-2141.2000.02197.x. PMID: 10997959.

dx.doi.org

Ali Guermazi i inni, Extranodal Hodgkin disease: spectrum of disease, „Radiographics”, 21 (1), 2001, s. 161–179, DOI: 10.1148/radiographics.21.1.g01ja02161, PMID: 11158651.

X. Huang i inni, Epidemiology of classical Hodgkin lymphoma and its association with Epstein Barr virus in Northern China, „PLoS One”, 6 (6), 2011, e21152, DOI: 10.1371/journal.pone.0021152, PMID: 21695175.

R. Kashyap i inni, Extranodal manifestations of lymphoma on [¹⁸F]FDG-PET/CT: a pictorial essay, „Cancer Imaging”, 11, 2011, s. 166–174, DOI: 10.1102/1470-7330.2011.0023, PMID: 22123338.

Arnold B. Gelb i inni, Pregnancy-associated lymphomas. A clinicopathologic study, „Cancer”, 78 (2), 1996, s. 304–310, DOI: 10.1002/(SICI)1097-0142(19960715)78:2<304::AID-CNCR18>3.0.CO;2-#, PMID: 8674008.

google.pl

books.google.pl

Vincent T. DeVita, Theodore S. Lawrence, Steven A. Rosenberg: Cancer: Principles and Practice of Oncology-Advances in Oncology. Lippincott Williams & Wilkins, 2010, s. 76. ISBN 978-1-4511-0314-4.

Ivor J. Benjamin, Robert C. Griggs, Edward J. Wing, J. Gregory Fitz: Andreoli and Carpenter’s Cecil Essentials of Medicine. Elsevier Health Sciences, 2015, s. 527. ISBN 978-1-4377-1899-7.

Andreas Engert, Anas Younes: Hodgkin Lymphoma: A Comprehensive Overview. Springer, 2016, s. 54–55. ISBN 978-3-319-12505-3.

Georg Lenz, Laura Pasqualucci: Malignant Lymphomas: Biology and Molecular Pathogenesis. Walter de Gruyter GmbH & Co KG, 2016, s. 261–262. ISBN 978-3-11-036691-4.

Stuart H. Orkin, David G. Nathan, David Ginsburg, A. Thomas Look, David E. Fisher, Samuel Lux IV, David E. Fisher: Oncology of Infancy and Childhood. Elsevier Health Sciences, 2009, s. 428. ISBN 978-1-4377-2138-6.

nih.gov

ncbi.nlm.nih.gov

Ali Guermazi i inni, Extranodal Hodgkin disease: spectrum of disease, „Radiographics”, 21 (1), 2001, s. 161–179, DOI: 10.1148/radiographics.21.1.g01ja02161, PMID: 11158651.

W. Townsend, D. Linch. Hodgkin’s lymphoma in adults. „Lancet”. 380 (9844), s. 836–847, wrzesień 2012. DOI: 10.1016/S0140-6736(12)60035-X. PMID: 22835602.

N.L. Wood, C.A. Coltman. Localized primary extranodal Hodgkin’s disease. „Ann Intern Med”. 78 (1), s. 113–118, styczeń 1973. PMID: 4565899.

R.K. Thomas i inni, Epidemiology and etiology of Hodgkin’s lymphoma, „Annals of Oncology”, 13 Suppl 4, 2002, s. 147–152, PMID: 12401681 [zarchiwizowane z adresu 2016-01-22].

C. Agostinelli, S. Pileri. Pathobiology of hodgkin lymphoma. „Mediterr J Hematol Infect Dis”. 6 (1), s. e2014040, 2014. DOI: 10.4084/MJHID.2014.040. PMID: 24959337.

R. Kashyap i inni, Extranodal manifestations of lymphoma on [¹⁸F]FDG-PET/CT: a pictorial essay, „Cancer Imaging”, 11, 2011, s. 166–174, DOI: 10.1102/1470-7330.2011.0023, PMID: 22123338.

R. Küppers, A. Engert, M.L. Hansmann. Hodgkin lymphoma. „J Clin Invest”. 122 (10), s. 3439–3447, październik 2012. DOI: 10.1172/JCI61245. PMID: 23023715.

K. Farrell, R.F. Jarrett. The molecular pathogenesis of Hodgkin lymphoma. „Histopathology”. 58 (1), s. 15–25, styczeń 2011. DOI: 10.1111/j.1365-2559.2010.03705.x. PMID: 21261680.

Y. Zhuang, A. Jackson, L. Pan, K. Shen i inni. Regulation of E2A gene expression in B-lymphocyte development. „Mol Immunol”. 40 (16), s. 1165–1177, marzec 2004. PMID: 15104122.

R. Küppers. Molecular biology of Hodgkin lymphoma. „Hematology Am Soc Hematol Educ Program”, s. 491–496, 2009. DOI: 10.1182/asheducation-2009.1.491. PMID: 20008234.

S. Prince, S. Keating, C. Fielding, P. Brennan i inni. Latent membrane protein 1 inhibits Epstein-Barr virus lytic cycle induction and progress via different mechanisms. „J Virol”. 77 (8), s. 5000–5007, kwiecień 2003. PMID: 12663807.

F. Emmerich, M. Meiser, M. Hummel, G. Demel i inni. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. „Blood”. 94 (9), s. 3129–3134, listopad 1999. PMID: 10556199.

S. Joos, C.K. Menz, G. Wrobel, R. Siebert i inni. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. „Blood”. 99 (4), s. 1381–1387, luty 2002. PMID: 11830490.

J.I. Martín-Subero, S. Gesk, L. Harder, T. Sonoki i inni. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. „Blood”. 99 (4), s. 1474–1477, luty 2002. PMID: 11830502.

W. Vainchenker, S.N. Constantinescu. JAK/STAT signaling in hematological malignancies. „Oncogene”. 32 (21), s. 2601–2613, maj 2013. DOI: 10.1038/onc.2012.347. PMID: 22869151.

S.M. Ansell. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. „Am J Hematol”. 89 (7), s. 771–779, lipiec 2014. DOI: 10.1002/ajh.23750. PMID: 24953862.

M. Fraga, J. Forteza. Diagnosis of Hodgkin’s disease: an update on histopathological and immunophenotypical features. „Histol Histopathol”. 22 (8), s. 923–935, sierpień 2007. PMID: 17503349.

O.W. Press, M. LeBlanc, A.S. Lichter, T.M. Grogan i inni. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. „J Clin Oncol”. 19 (22), s. 4238–4244, listopad 2001. PMID: 11709567.

M. Loeffler, O. Brosteanu, D. Hasenclever, M. Sextro i inni. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. „J Clin Oncol”. 16 (3), s. 818–829, marzec 1998. PMID: 9508162.

L. Specht, R.G. Gray, M.J. Clarke, R. Peto. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin’s disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin’s Disease Collaborative Group. „J Clin Oncol”. 16 (3), s. 830–843, marzec 1998. PMID: 9508163.

P. Seam, J.E. Janik, D.L. Longo, V.T. Devita. Role of chemotherapy in Hodgkin’s lymphoma. „Cancer J”. 15 (2). s. 150–154. DOI: 10.1097/PPO.0b013e3181a27018. PMID: 19390311.

J.B. Nachman, R. Sposto, P. Herzog, G.S. Gilchrist i inni. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. „J Clin Oncol”. 20 (18), s. 3765–3771, wrzesień 2002. PMID: 12228196.

S.J. Horning, R.T. Hoppe, S. Breslin, N.L. Bartlett i inni. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. „J Clin Oncol”. 20 (3), s. 630–637, luty 2002. PMID: 11821442.

V.T. DeVita, R.M. Simon, S.M. Hubbard, R.C. Young i inni. Curability of advanced Hodgkin’s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. „Ann Intern Med”. 92 (5), s. 587–595, maj 1980. PMID: 6892984.

P.J. Bierman, R.G. Bagin, S. Jagannath, J.M. Vose i inni. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. „Ann Oncol”. 4 (9), s. 767–773, listopad 1993. PMID: 8280658.

A. Josting, I. Kàtay, U. Rueffer, S. Winter i inni. Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). „Ann Oncol”. 9 (3), s. 289–295, marzec 1998. PMID: 9602263.

D.C. Linch, D. Winfield, A.H. Goldstone, D. Moir i inni. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. „Lancet”. 341 (8852), s. 1051–1054, kwiecień 1993. PMID: 8096958.

C.H. Moskowitz, T. Kewalramani, S.D. Nimer, M. Gonzalez i inni. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin’s disease. „Br J Haematol”. 124 (5), s. 645–652, marzec 2004. PMID: 14871252.

C.H. Moskowitz, S.D. Nimer, A.D. Zelenetz, T. Trippett i inni. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. „Blood”. 97 (3), s. 616–623, luty 2001. PMID: 11157476.

M. Lishner. Cancer in pregnancy. „Ann Oncol”. 14 Suppl 3, s. iii31-6, 2003. PMID: 12821536.

K.M. Kelly. Hodgkin lymphoma in children and adolescents: improving the therapeutic index. „Blood”. 126 (22), s. 2452–2458, listopad 2015. DOI: 10.1182/blood-2015-07-641035. PMID: 26582374.

M. Koshy, A. Fairchild, C.H. Son, U. Mahmood. Improved survival time trends in Hodgkin’s lymphoma. „Cancer Med”. 5 (6), s. 997–1003, czerwiec 2016. DOI: 10.1002/cam4.655. PMID: 26999817.

A. Ahmadzadeh, M.S. Yekaninejad, M.H. Jalili, M. Bahadoram i inni. Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin’s Lymphoma Patients with Chemotherapy Regimens. „Int J Hematol Oncol Stem Cell Res”. 8 (2), s. 21–26, 2014. PMID: 24800035.

R.L. Siegel, K.D. Miller, A. Jemal. Cancer statistics, 2015. „CA Cancer J Clin”. 65 (1). s. 5–29. DOI: 10.3322/caac.21254. PMID: 25559415.

G. Bonadonna, T. Hodgkin. Historical review of Hodgkin’s disease. „Br J Haematol”. 110 (3), s. 504–511, wrzesień 2000. DOI: 10.1046/j.1365-2141.2000.02197.x. PMID: 10997959.

G.S. Seif, A.I. Spriggs. Chromosome changes in Hodgkin’s disease. „J Natl Cancer Inst”. 39 (3), s. 557–570, wrzesień 1967. PMID: 6053720.

W.R. Boecker, D.K. Hossfeld, W.M. Gallmeier, C.G. Schmidt. Clonal growth of Hodgkin cells. „Nature”. 258 (5532), s. 235–236, listopad 1975. PMID: 1081649.

R. Lakhtakia, I. Burney. A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma. „Sultan Qaboos Univ Med J”. 15 (2), s. e202-6, maj 2015. PMID: 26052452. PMCID: PMC4450782.

V.T. Devita, A.A. Serpick, P.P. Carbone. Combination chemotherapy in the treatment of advanced Hodgkin’s disease. „Ann Intern Med”. 73 (6), s. 881–895, grudzień 1970. PMID: 5525541.

G. Bonadonna, R. Zucali, S. Monfardini, M. De Lena i inni. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. „Cancer”. 36 (1), s. 252–259, lipiec 1975. PMID: 54209.

pubmed.ncbi.nlm.nih.gov

Chłoniak Hodgkina (Polish Wikipedia)

archive.is

archive.org

ascopubs.org

jco.ascopubs.org

ascopubs.org

ashpublications.org

cancer.gov

seer.cancer.gov

czytelniamedyczna.pl

doi.org

doi.org

dx.doi.org

google.pl

books.google.pl

haematologica.org

mp.pl

nejm.org

nih.gov

ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov

onkologia.org.pl

oxfordjournals.org

annonc.oxfordjournals.org

rsna.org

pubs.rsna.org

scirp.org

thelancet.com

um.es

hh.um.es

web.archive.org

wiley.com

onlinelibrary.wiley.com